Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4348760 | 0.84 | EPHX2 (0.53) | HTTALDH1A1MAPTEPHX2 | |
| SCHEMBL4350868 | 0.81 | SMN1; SMN2 (0.55) | HTTSMN1; SMN2LMNATDP1HPGD | |
| SCHEMBL4355451 | 0.79 | ALDH1A1 (0.60) | HTTSMN1; SMN2LMNAHPGDALDH1A1 | |
| SCHEMBL4348481 | 0.76 | SMN1; SMN2 (0.57) | HTTSMN1; SMN2LMNATDP1HPGD | |
| SCHEMBL4356036 | 0.76 | HTT (0.60) | HTTSMN1; SMN2LMNAALDH1A1RECQL | |
| SCHEMBL4351301 | 0.75 | SMN1; SMN2 (0.60) | HTTSMN1; SMN2LMNAHPGDALDH1A1 | |
| SCHEMBL10942210 | 0.75 | L3MBTL1 (0.48) | SMN1; SMN2TDP1HPGDALDH1A1KDM4E | |
| SCHEMBL12260118 | 0.75 | L3MBTL1 (0.48) | SMN1; SMN2TDP1HPGDALDH1A1KDM4E | |
| SCHEMBL4349397 | 0.74 | SMN1; SMN2 (0.52) | HTTSMN1; SMN2LMNAHPGDALDH1A1 | |
| SCHEMBL4357518 | 0.74 | POLB (0.47) | HTTSMN1; SMN2LMNAHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | JERINI AG (DE) | 2011-03-17 | — | — | US | claimed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | claimed |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | JERINI AG (DE) | 2007-03-08 | — | — | US | claimed |
| CN-1701061-A | Novel compounds for inhibiting rotamase enzymes and uses thereof | JERINI AG (DE) | 2005-11-23 | — | — | CN | claimed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | NR1I3, NR1D1, NR1D2 | HTT 3824/4885SMN1; SMN2 1791/4885LMNA 3160/4885 |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | NR1I3, NR1D1, NR1D2 | HTT 3995/4885SMN1; SMN2 3250/4885LMNA 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.